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ABSTRACT
Hepatitis C virus (HCV) is a significant contributor to the global disease 
burden, and development of an effective vaccine is required to eliminate 
HCV infections worldwide. CD4+ and CD8+ T cell immunity correlates with 
viral clearance in primary HCV infection, and intrahepatic CD8+ tissue-
resident memory T (TRM) cells provide lifelong and rapid protection against 
hepatotropic pathogens. Consequently, we aimed to develop a vaccine to 
elicit HCV-specific CD4+ and CD8+ T cells, including CD8+ TRM cells, in the 
liver, given that HCV primarily infects hepatocytes. To achieve this, we 
vaccinated wild-type BALB/c mice with a highly immunogenic cytolytic DNA 
vaccine encoding a model HCV (genotype 3a) nonstructural protein (NS5B) 
and a mutant perforin (pVAX-NS5B-PRF), as well as a recombinant adeno-
associated virus (AAV) encoding NS5B (rAAV-NS5B). A novel fluorescent 
target array (FTA) was used to map immunodominant CD4+ T helper (TH) cell 
and cytotoxic CD8+ T cell epitopes of NS5B in vivo, which were subsequently 
used to design a KdNS5B451-459 tetramer and analyze NS5B-specific T cell 
responses in vaccinated mice in vivo. The data showed that intradermal 
prime/boost vaccination with pVAX-NS5B-PRF was effective in eliciting TH and
cytotoxic CD8+ T cell responses and intrahepatic CD8+ TRM cells, but a single 
intravenous dose of hepatotropic rAAV-NS5B was significantly more effective.
As a T-cell-based vaccine against HCV should ideally result in localized T cell 
responses in the liver, this study describes primary observations in the 
context of HCV vaccination that can be used to achieve this goal.
IMPORTANCE: There are currently at least 71 million individuals with chronic 
HCV worldwide and almost two million new infections annually. Although the 
advent of direct-acting antivirals (DAAs) offers highly effective therapy, 
considerable remaining challenges argue against reliance on DAAs for HCV 
elimination, including high drug cost, poorly developed health infrastructure, 
low screening rates, and significant reinfection rates. Accordingly, 
development of an effective vaccine is crucial to HCV elimination. An HCV 
vaccine that elicits T cell immunity in the liver will be highly protective for 
the following reasons: (i) T cell responses against nonstructural proteins of 
the virus are associated with clearance of primary infection, and (ii) long-
lived liver-resident T cells alone can protect against malaria infection of 
hepatocytes. Thus, in this study we exploit promising vaccination platforms 
to highlight strategies that can be used to evoke highly functional and long-
lived T cell responses in the liver for protection against HCV.
KEYWORDS: adeno-associated virus vaccine, cytotoxic T cells, DNA vaccine, 
helper T cells, hepatitis C virus vaccine, liver immunity
INTRODUCTION
At least 71 million people are persistently infected with hepatitis C virus 
(HCV) worldwide, and every year 1.75 million new infections and 399,000 
HCV-related deaths are reported (1, 2). Although the new direct-acting 
antivirals (DAAs) cure >95% of infected individuals, there are still major 
challenges to overcome in order to achieve the WHO Hepatitis C Global 
Elimination Goals by 2030. First, only 20% of infected individuals worldwide 
are diagnosed. Second, DAAs remain prohibitively costly for much of the 
developing world. Third, the health infrastructure to deliver treatment to 
marginalized people who inject drugs (PWID) remains underdeveloped. 
Finally, successful DAA treatment does not prevent reinfection (1, 2). Thus, 
the development of an effective vaccine is crucial to eliminating HCV 
worldwide.
HCV is a rapidly mutating RNA virus comprising 8 genotypes and at least 67 
subtypes, which vary in regional and global distribution (3), making the 
development of a prophylactic HCV vaccine extremely challenging. However,
approximately 25% of individuals clear the virus during primary infection (4),
and consequently, development of a vaccine that can elicit immune 
responses that correlate with natural clearance represents a rational path for
HCV vaccine design (5). Although broadly neutralizing antibodies are targets 
for HCV vaccine development (6, 7), there is a significant emphasis on 
developing T-cell-mediated HCV vaccines because robust CD4+ and CD8+ T 
cell responses that target the conserved nonstructural (NS) proteins of the 
virus correlate with clearance of the virus from primary infection (8–10). In 
these individuals, robust and broad T cell responses against HCV NS protein 
epitopes are thought to eliminate virus-infected cells during acute stages of 
infection in order to prevent persistent infection (5). This is an acceptable 
vaccination outcome given that acute infections do not cause serious disease
and are often subclinical (5). Furthermore, the only HCV vaccine candidate to
have advanced to phase IIb clinical trials thus far exploits vaccine vectors 
encoding genotype 1 (gt1) NS proteins in a prime/boost regimen to elicit 
systemic T cell immunity (11).
Since HCV primarily replicates in hepatocytes, a vaccine designed to elicit T 
cell responses to the NS proteins should also aim to localize these responses 
to the liver. In this regard, the ability of an HCV vaccine to elicit intrahepatic 
CD8+ tissue-resident memory T (TRM) cells will be important since several 
studies in mice and humans suggest that these cells correlate strongly with 
protection against hepatotropic pathogens, including malaria parasites (12, 
13), hepatitis B virus (HBV) (14), and HCV (15). Circulating memory T cells, 
which include central memory T (TCM) cells and effector memory T (TEM) cells, 
take some time to migrate to the site of an infection, whereas localized TRM 
cells, which reside in tissues for the life span of the individual (16), can 
respond more rapidly. Intrahepatic CD8+ TRM cells produce higher levels of 
antiviral cytokines such as gamma interferon and are more cytotoxic than 
CD8+ TEM cells (12). There is a strong genetic bottleneck associated with HCV 
transmission as only one or a few variants, known as transmitted/founder (T/
F) viruses, establish infection following transmission (17). The T/F viruses 
persist in the new host as the dominant variants mediating infection for 
∼100 days before divergent quasispecies emerge, escaping immune 
selection pressures to establish persistent infection (17). Thus, the presence 
of intrahepatic CD8+ TRM cells at the time of transmission could facilitate 
rapid elimination of the virus before the evolving quasispecies facilitate 
immune escape. Several other studies have shown that CD8+ TRM cells are 
also crucial for protection against virus infections that occur in different 
anatomical sites such as the skin, lungs, female reproductive tract, and 
vagina (18–23).
The first study to describe a vaccination regimen to elicit protective CD8+ TRM
cells used a “prime/pull” approach in which systemically primed antiviral 
CD8+ T cells were “pulled” or recruited to the vagina by intravaginal topical 
application of the chemokine ligands CXCL9 and CXCL10 (18). The 
“prime/trap” vaccination regimen, an adaptation of the “prime/pull” 
approach, was recently shown to generate antigen-specific CD8+ TRM cells in 
the liver of vaccinated mice that protected against challenge with 
Plasmodium berghei sporozoites (12). This study involved priming adoptively
transferred T cell receptor (TCR) transgenic CD8+ T cells (PbT-I) with a P. 
berghei peptide immunogen (NVY) fused to an antibody that delivers the 
immunogen to cross-presenting dendritic cells (DCs). The vast majority of 
the primed CD8+ PbT-I cells differentiated into TRM cells and consequently 
were “trapped” in the liver following an intravenous (i.v.) boost with a 
hepatotropic recombinant adeno-associated virus (rAAV) encoding NVY. 
Depletion of P. berghei-specific CD8+ TRM cells in the liver confirmed that 
these cells were crucial for protection against P. berghei sporozoite challenge
(12).
We have demonstrated that a cytolytic DNA vaccine encoding a mutant form
of perforin (PRF) and an immunogen (ribosomal DNA [rDNA]-PRF) is more 
effective than canonical DNA vaccines not encoding PRF in eliciting 
protection against a surrogate human immunodeficiency virus challenge, 
EcoHIV, of mice (24) and T cell immunity in mice and pigs (25–27). rDNA-PRF,
unlike canonical DNA, induces necrosis (mimicking a lytic virus infection) in 
transfected cells resulting in the release of intrinsic danger-associated 
molecular patterns (DAMPs), which activate DCs to cross-present antigens to 
naive CD8+ T cells (28). Consequently, immunization with rDNA-PRF is more 
effective than canonical DNA in priming naive CD8+ T cells to become 
effector cells (28). The cytolytic DNA platform was engineered using the 
pVAX plasmid DNA backbone, which is FDA approved for use in humans and 
can be used to encode multiple HCV NS proteins and elicit multigenotypic 
(gt1 and gt3) HCV-specific T cell responses (29).
Although the malaria study (12) provides seminal proof of concept, an 
analogous vaccination regimen using vaccine vectors encoding native 
proteins to elicit polyclonal intrahepatic CD8+ TRM cells and CD4+ T cell 
responses against HCV has not been evaluated or developed. DNA and AAV 
vectors have been tested extensively and have been shown to be safe and 
effective for vaccination and gene therapy in humans (30, 31). Thus, in this 
study, we report the use of cytolytic DNA and a hepatotropic AAV vector 
encoding a codon-optimized gt3a HCV protein, NS5B, in prime/trap and 
prime/boost vaccination regimens to elicit T cell responses and intrahepatic 
CD8+ TRM cells in vivo. Furthermore, we also identified novel 
immunodominant CD4+ T helper (TH) cell and CD8+ T cell epitopes of NS5B in 
wild-type BALB/c mice, which were used to thoroughly analyze NS5B-specific 
TH cell and CD8+ T cell responses in vivo.
RESULTS
Identification of an NS5B immunodominant CD8+ T cell epitope for tetramer 
synthesis.We have previously shown that HCV (gt3a) NS5B is a highly 
immunogenic protein (29) and can therefore serve as a model antigen to 
optimize an rDNA/rAAV-based vaccination strategy to elicit HCV-specific T 
cell immunity. However, the immunodominant CD8+ T cell epitopes of NS5B 
in BALB/c mice, necessary to synthesize a tetramer in order to detect NS5B-
specific CD8+ T cells, are unknown. Consequently, we modified a fluorescent 
target array (FTA) assay (32–34) to map the most immunodominant TH and 
CD8+ T cell epitopes of NS5B in vivo in mice vaccinated with cytolytic DNA 
encoding NS5B (pVAX-NS5B-PRF). The assay introduces fluorescently labeled
bar-coded autologous naive splenocytes pulsed with viral peptides (i.e., the 
FTA) into previously immunized mice to evaluate the magnitude and/or 
avidity of TH cell and cytotoxic CD8+ T cell responses in vivo (32–34). 
Traditional peptide-based mapping and T cell stimulation assays such as 
enzyme-linked immunosorbent spot (ELISpot) and intracellular cytokine 
staining (ICS) analyses do not distinguish CD4+ and CD8+ T cell responses 
and/or involve prolonged culture/manipulation of T cells in vitro. We have 
previously shown that NS5B peptide pool 3 (P3) contains the most 
immunodominant CD8+ T cell epitopes in BALB/c mice (29). Therefore, we 
generated an FTA using naive splenocytes pulsed with each or all of the 
peptides in P3 and injected these cells i.v. into mice previously vaccinated 
via the intradermal (i.d.) route with pVAX-NS5B-PRF or the pVAX-PRF (mock) 
control (Fig. 1A). Following recovery of the FTA targets from the spleen and 
the liver 15 h after the i.v. injection, NS5B-specific T cell responses were 
assessed by analysis of the population of the FTA cells using flow cytometry 
(Fig. 1). The greatest NS5B-specific CD8+ cytotoxic T cell responses were 
detected against targets pulsed with peptides 69 (NS5B442–459) and 70 
(NS5B449–466) or P3 (positive control) (Fig. 1B). A common 9-amino-acid (aa) 
epitope (TYSVTPLDL [NS5B451–459]) was identified in both peptides 69 and 70 
using bioinformatics analysis as described in Materials and Methods, which 
was used to synthesize a KdNS5B451–459 tetramer for the analysis of NS5B-
specific CD8+ T cells and intrahepatic CD8+ TRM cells.
Identification of immunodominant TH cell epitopes of NS5B. 
Clinical data suggest that the presence of TH cells that could mobilize CD8+ T 
cell responses is a robust correlate of clearance from primary HCV infection 
(9). TH cells recognize cognate peptide:major histocompatibility complex 
class II (MHC-II) molecules presented on B (B220+) cells and deliver 
activation signals (i.e., costimulation) to B cells resulting in the upregulation 
of CD69 on antigen-presenting B220+ cells (29, 33, 34). Therefore, the 
geometric mean fluorescent intensity (GMFI) of CD69 expression on peptide-
pulsed B220+ targets in an FTA is a direct measure of the TH cell responses in
vivo (29, 33, 34), and this analysis was used to map the immunodominant TH 
cell epitope within P3 of NS5B (Fig. 2). We conducted the mapping analysis 
using B220+ FTA cells recovered from the spleens of vaccinated mice (Fig. 2),
given that NS5B-specific TH cell responses were not significantly detected in 
the liver of pVAX-NS5B-PRF-vaccinated mice compared to the mock control. 
The data showed that the greatest upregulation of CD69 occurred on B220+ 
cells pulsed with peptide 77 (NS5B495–512) in pVAX-NS5B-PRF-vaccinated mice 
compared to other peptides in P3 and the respective peptide-pulsed B220+ 
cell population in the mock-vaccinated mice (Fig. 2). We have previously 
reported that TH cell responses were detected against peptide pool 2 (P2) of 
NS5B (NS5B197–395) (29). Therefore, the immunodominant TH cell epitopes 
within P2 were also mapped using an FTA analysis similar to that described 
in the legend to Fig. 2 which showed peptide 36 (NS5B225–240) to be the 
immunodominant TH cell epitope in P2 (data not shown).
In order to confirm whether NS5B225–240 and NS5B495–512 were indeed CD4+ TH 
cell epitopes, CD4+ T cells were depleted in pVAX-NS5B-PRF-vaccinated mice 
prior to the FTA challenge (Fig. 2C and D). Data showed that upregulation of 
CD69 on B220+ FTA cells pulsed with NS5B225–240, NS5B495–512, P2, or P3 was 
only observed in pVAX-NS5B-PRF-vaccinated mice with an intact CD4+ cell 
compartment (Fig. 2C and D). The B cell responses in the pVAX-NS5B-PRF-
vaccinated mice in which CD4+ cells were depleted was comparable to that 
of mock-vaccinated mice (Fig. 2C and D). Thus, the mapped NS5B225–240 and 
NS5B495–512 represent immunodominant CD4+ TH cell epitopes of NS5B in 
BALB/c mice.
Overall, the FTA-based T cell epitope mapping analyses of gt3a NS5B 
revealed an immunodominant CD8+ T cell epitope (NS5B451–459) and 
immunodominant TH cell epitopes (NS5B225–240 and NS5B495–512) for the analysis
of NS5B-specific T cell responses in BALB/c mice.
Evaluation of DNA- and AAV-based vaccination regimens to elicit systemic 
and intrahepatic NS5B-specific CD8+ T cells.
The first “prime and trap” study (12) elicited liver CD8+ TRM cells using a 
peptide (NVY) antigen from P. berghei and TCR transgenic CD8+ T cells. We 
evaluated whether this approach could be adapted to a more physiological 
vaccination setting when rDNA-PRF, which can encode multiple NS antigens 
(26, 29), was used to prime endogenous polyclonal T cells. Our studies and 
others have shown that after i.d. immunization of mice with a 50-μg dose of 
plasmid DNA, the expression of DNA-encoded immunogens peaks within 24 h
and DCs initiate priming of naive CD8+ T within 2 days (24, 35, 36). 
Therefore, following a modified “prime/trap” vaccination protocol we 
immunized BALB/c mice i.d. with 50 μg of pVAX-NS5B-PRF (prime) 2 days 
prior to i.v. immunization with 5 × 109 viral genome copies (vgc) of rAAV-
NS5B (trap) and 14 days prior to a booster immunization with pVAX-NS5B-
PRF (rDNA/rAAV/rDNA) (Fig. 3A). A placebo control regimen and vaccination 
regimens that only included pVAX-NS5B-PRF (rDNA/mock/rDNA) or rAAV-
NS5B (mock/rAAV/mock) were used as relevant comparative controls for the 
rDNA/rAAV/rDNA regimen (Fig. 3A). We have previously determined that 5 × 
109 vgc of rAAV-NS5B results in the transduction of ∼10% of mouse 
hepatocytes in vivo (data not shown) and have shown that a similar dose of 
rAAV can elicit robust CD8+ T cell responses in the liver (37). Furthermore, 
Fernandez-Ruiz et al. (12) showed that an rAAV dose that resulted in ∼10% 
transduction of hepatocytes was suitable for trapping primed CD8+ T cells.
Using the KdNS5B451–459 tetramer (synthesized as described above), we 
initially evaluated the number of NS5B-specific CD8+ T cells elicited 7 and 42 
days after the final vaccination in each regimen described above (Fig. 3A). At
both time points, the number of NS5B-specific CD8+ T cells in the liver was 
higher after vaccination with regimens that included pVAX-NS5B-PRF and/or 
rAAV-NS5B compared to the placebo control (Fig. 3). This trend was also 
observed in the spleen, although this was not statistically significant when 
the responses in rDNA/rAAV/rDNA- and mock/rAAV/mock-vaccinated mice 
were compared to those in the placebo control at day 7 (Fig. 3B). Similar 
numbers of NS5B-specific CD8+ T cells developed in the liver and the spleen 
of rDNA/rAAV/rDNA, rDNA/mock/rDNA, and mock/rAAV/mock vaccination 
regimens 7 days after the final vaccination (Fig. 3B). A similar trend was 
observed in the spleen 42 days after the final vaccination, but 
rDNA/rAAV/rDNA and mock/rAAV/mock regimens elicited significantly higher 
numbers of NS5B-specific CD8+ T cells in the liver compared to 
rDNA/mock/rDNA (Fig. 3C). This suggests that a single exposure to rAAV-
NS5B was sufficient to elicit a durable population of intrahepatic NS5B-
specific CD8+ T cells, even in the absence of priming and boosting with 
pVAX-NS5B-PRF.
A vaccination regimen to promote intrahepatic CD8+ TRM cells.
The effectiveness of a vaccine is dependent on its ability to elicit 
immunological memory and the memory CD8+ T cell population can be 
broadly categorized into TCM, TEM, and TRM cells (16). Intrahepatic CD8+ TRM 
cells can be distinguished from circulating memory CD8+ T cells based on the
expression of CD69 and CD62L using flow cytometry: TCM (CD69− CD62L+), 
TRM (CD69+ CD62L−), and TEM (CD69− CD62L−) (12). Thus, using this 
categorization and flow cytometric analysis of KdNS5B451–459 tetramer+ CD8+ 
cells, we assessed whether exposure to rAAV-NS5B facilitates the 
development of high numbers of TRM cells during the memory phase (day 42) 
following vaccination. The results showed that the majority of the NS5B-
specific CD8+ T cells were identified as TRM cells in the liver and TEM cells in 
the spleen in mice exposed to rAAV-NS5B in the rDNA/rAAV/rDNA and 
mock/rAAV/mock regimens (Fig. 4A). Furthermore, similar numbers of 
intrahepatic NS5B-specific CD8+ TRM and TEM cells were elicited between 
rDNA/rAAV/rDNA and mock/rAAV/mock regimens (Fig. 4B). Although the 
rDNA/rAAV/rDNA and mock/rAAV/mock regimens elicited the greatest 
numbers of intrahepatic NS5B-specific CD8+ TRM and TEM cells, the 
rDNA/mock/rDNA regimen was able to elicit NS5B-specific CD8+ TRM and TEM 
cells in the liver compared to the placebo control (Fig. 4B). In contrast to the 
observations in the liver, similar numbers of NS5B-specific CD8+ TCM, TEM, and 
TRM cells were elicited in the spleen by the rDNA/rAAV/rDNA, 
mock/rAAV/mock, and rDNA/mock/rDNA regimens (Fig. 4B).
Similar numbers of intrahepatic NS5B-specific CD8+ T cells were elicited 7 
days following prime/boost vaccination with pVAX-NS5B-PRF (i.e., in the 
rDNA/mock/rDNA regimen) compared to the rDNA/rAAV/rDNA and 
mock/rAAV/mock regimens (Fig. 3A). Therefore, we proposed that rAAV-NS5B
vaccination would elicit high numbers of intrahepatic NS5B-specific CD8+ TRM 
cells more effectively if rAAV-NS5B was delivered 7 days after prime/boost 
vaccination (at 14-day intervals) with pVAX-NS5B-PRF (i.e., in an rDNA/rDNA/
rAAV regimen rather than the rDNA/rAAV/rDNA regimen) compared to a 
single vaccination with rAAV-NS5B. However, this was not the case, and the 
numbers of NS5B-specific CD8+ T cells and intrahepatic CD8+ TRM cells 
elicited by the modified rDNA/rDNA/rAAV regimen and a single vaccination 
with rAAV-NS5B were similar (data not shown).
Overall, this analysis suggests that the ability of rAAV-NS5B to elicit robust 
memory intrahepatic NS5B-specific CD8+ T cells (Fig. 3B) correlated with its 
ability to promote the development of antiviral CD8+ TRM cells in the liver 
(Fig. 4B).
Heightened expression of CD11a and CXCR3 on intrahepatic NS5B-specific 
CD8+ TRM cells following rAAV-NS5B vaccination.
Although the above studies suggested that CD8+ TRM cells were detected in 
the liver, elevated expression of CD11a and chemokine (C-X-C motif receptor
3 [CXCR3]) is an authentic characteristic of these cells compared to 
circulating memory T cells (12, 38). Consequently, we examined the 
expression of CD11a and CXCR3 on the different populations of NS5B-
specific memory CD8+ T cell populations in the liver. Each vaccination 
regimen (rDNA/rAAV/rDNA, mock/rAAV/mock, and rDNA/mock/rDNA) 
upregulated CD11a and CXCR3 on intrahepatic NS5B-specific CD8+ TRM cells 
compared to the respective TEM and TCM populations, although this trend was 
subtle and not always statistically significant in the rDNA/mock/rDNA group 
(Fig. 5). Furthermore, CD11a expression on intrahepatic NS5B-specific CD8+ 
TRM cells that developed from the rDNA/rAAV/rDNA and mock/rAAV/mock 
regimens was significantly higher than the rDNA/mock/rDNA regimen (Fig. 5).
A similar yet more subtle trend was observed with respect to CXCR3 
expression on intrahepatic NS5B-specific CD8+ TRM cells that developed in 
rAAV-NS5B-vaccinated mice compared to mice vaccinated with the 
rDNA/mock/rDNA regimen. Flow cytometric analysis showed that in the 
placebo control group, only a small number of events were KdNS5B451-459 
tetramer+ CD8+ in the liver (Fig. 3B), while even fewer or no events 
represented NS5B-specific TEM, TRM, and TCM cells (Fig. 4A). Consequently, 
these mice were excluded from this analysis. Overall, these results suggest 
that rAAV-NS5B vaccination is more efficient than pVAX-NS5B-PRF 
vaccination to ensure heightened expression of CD11a and CXCR3 on 
intrahepatic NS5B-specific CD8+ TRM cells, which likely facilitates retention of 
these cells in the liver (see Discussion).
rAAV-NS5B vaccination elicits superior NS5B-specific TH cell and CD8+ T cell 
responses in vivo.
Next, we evaluated the functional activity of NS5B-specific CD8+ T cells (Fig. 
6 and Table 3) and TH cells (Fig. 7 and Table 4), not only against the 
immunodominant epitopes described above (Fig. 1 and 2) but also using the 
entire NS5B peptide set, 42 days after vaccination with the different 
regimens. As intrahepatic CD8+ TRM cells survive very poorly following in vitro
culture (12), the FTA analysis was used to examine the NS5B-specific T cell 
responses in vivo. Flow cytometric analysis of the FTA cells recovered from 
the spleen (Fig. 6B) and the liver (Fig. 6C) suggests that killing responses 
were significantly higher in rDNA/rAAV/rDNA-, mock/rAAV/mock-, and 
rDNA/mock/rDNA-vaccinated mice compared to the placebo control against 
target cells pulsed with P3, immunodominant NS5B442–459, or NS5B451–459. 
Modest or no responses were detected against target cells pulsed with NS5B 
peptide pool 1 (NS5B1–207 [P1]) or P2 compared to the placebo control (Fig. 6).
Robust killing responses against all target cells pulsed with titrated 
concentrations of NS5B451–459 were detected after vaccination with the 
rDNA/rAAV/rDNA, mock/rAAV/mock, and rDNA/mock/rDNA regimens, but the 
greatest NS5B451–459-specific killing responses were exhibited in rAAV-NS5B-
vaccinated mice (Fig. 6). A similar trend was observed against target cells 
pulsed with the NS5B442–459 peptide, although there was a dose-dependent 
reduction in killing responses against targets pulsed with 0.01 or 0.1 μg/ml 
reflective of a lower-avidity response to NS5B442–459- compared to NS5B451–459-
pulsed targets (Fig. 6).

Analysis of CD69 expression on B220+ cells in the FTA suggests that mice 
vaccinated with rDNA/rAAV/rDNA, mock/rAAV/mock, or rDNA/mock/rDNA 
exhibited TH cell responses significantly above those in the placebo control 
against target cells pulsed with 10 μg/ml of NS5B225–240, NS5B495–512, or NS5B 
P2 (NS5B197–395) (Fig. 7). Although the TH cell responses were similar against 
spleen-derived target cells pulsed with 10 μg/ml of NS5B225–240 peptide in all 
regimens except the placebo (Fig. 7A), the highest TH cell responses were 
elicited by the rDNA/rAAV/rDNA and mock/rAAV/mock regimens. 
Furthermore, only mice in the rDNA/rAAV/rDNA and mock/rAAV/mock 
regimens elicited TH cell responses against targets pulsed with P1 that were 
greater than the placebo control. Superior TH cell responses after vaccination
with the rDNA/rAAVr/DNA and mock/rAAV/mock regimens were also observed
against B220+ FTA cells pulsed with 1 μg/ml of NS5B225–240 or NS5B495–512, 
particularly those recovered from the spleen (Fig. 7). TH cell responses to 
target cells pulsed with P3 are not shown as these targets were virtually all 
killed when introduced into mice vaccinated with a regimen that included 
rAAV-NS5B, as shown in Fig. 6.
DISCUSSION
The development of a HCV vaccine is a global priority. Modeling studies 
suggest that using a vaccine that is 50 to 80% effective in a high-risk 
population can considerably reduce the incidence of persistent HCV infection
(39). An effective vaccine is considered essential to meet the WHO’s 
Sustainable Development Goal of eliminating 90% of incident hepatitis C by 
2030 (2). After 2 decades of preclinical studies and phase I HCV vaccine 
trials, the current lead candidate is under investigation in an NIH-sponsored 
phase IIb, placebo-controlled trial in high-risk PWID in a prime/boost regimen 
of gt1 NS antigens delivered via chimpanzee adenovirus and then modified 
vaccinia virus Ankara vaccines (11). Although this vaccine induces robust 
systemic T cell immunity to gt1b antigens, it is not known whether similar 
responses are elicited in the liver (11). The efficacy of any HCV vaccine 
based on T cell immunity will be dependent on the rapid induction of robust 
HCV-specific T cell responses in the liver following HCV infection (40), and 
consequently, a vaccine that elicits intrahepatic HCV-specific CD8+ TRM cells 
and CD4+ T cell immunity likely has an intrinsic advantage. Recently, robust 
liver-resident CD8+ T cell responses elicited following vaccination were 
shown to be crucial for protection against controlled human malaria infection
and P. berghei infection in mice (12, 13). Recombinant DNA and rAAV vectors
have been regularly used as vectors for vaccination and gene therapy in 
humans. Thus, for the first time, we evaluated the use of recombinant DNA- 
and rAAV-based vaccination strategies to elicit intrahepatic HCV-specific T 
cell immunity and CD8+ TRM cells in vivo.
Previous studies exploiting AAV as a vector to elicit intrahepatic T cell 
immunity and TRM cells have exploited AAV encoding a single or a few T cell 
epitopes and TCR transgenic T cells in adoptive transfer settings (12, 37). As 
native proteins are more susceptible to cross-presentation than a single or a 
few CD8+ T cell epitopes encoded by vaccine vectors (41), the current study 
exploited vaccine vectors encoding codon-optimized gt3a NS5B protein and 
evaluated T cell immunity in a polyclonal repertoire in wild-type mice.
The current study described the use of the FTA assay to map 
immunodominant T cell epitopes of gt3a NS5B in vivo. Our in vivo FTA-based 
epitope mapping analysis also led to the primary development of a functional
KdNS5B451–459 tetramer and the identification of NS5B225–240 and NS5B495–512 
immunodominant peptides for the analysis of NS5B-specific TH cell responses
in BALB/c mice. We have previously reported that the FTA is a high-
throughput and versatile technique to measure the magnitude and avidity of 
CD4+ TH cell and CD8+ killer T cell responses in vivo (32–34). FTA overcomes 
many drawbacks associated with manipulating T cells and their functional 
parameters in vitro, which are common in conventional T cell stimulation 
assays such as ELISpot and ICS. Furthermore, CD8+ TRM cells and liver-
resident CD8+ TRM cells have been reported to survive poorly following in 
vitro culture (12, 16), which further highlights the importance of exploiting 
the FTA for epitope mapping and evaluating T cell responses.
Our data suggest that there is a strong correlation between the number of 
NS5B-specific CD8+ TRM cells, assessed using the KdNS5B451–459 tetramer, and 
the magnitude of NS5B451–459-specific cytotoxic CD8+ T cell responses in 
vaccinated mice as determined by the FTA analysis. These findings are 
consistent with our previous report showing that i.v. immunization with rAAV 
can elicit cytotoxic CD8+ T cells capable of killing cognate peptide-pulsed 
targets in vivo (37). Intravenous delivery is the best-established route to 
deliver substances to the liver, and the FTA target cells will be readily 
exposed in the liver following i.v. challenge in order to evaluate intrahepatic 
T cell responses. However, these target cells can circulate to other sites 
(e.g., the spleen), making them susceptible to T cell responses systemically. 
It is important for future studies to test the HCV vaccines, including those 
developed in the current study, in a challenge model that recapitulates 
hepatotropic HCV infection in order to gain insight into the protective role of 
intrahepatic TRM cells. Although a challenge model of this nature has not 
been developed to evaluate vaccine efficacy in wild-type mice, the recently 
developed Norway rat hepacivirus infection model (42) has the potential to 
be adopted for this purpose.
CD4+ TH cell responses as measured by the upregulation of CD69 on FTA 
B220+ cells were more readily detected in the FTA recovered from the spleen
compared to the liver in pVAX-NS5B-PRF- and/or rAAV-NS5B-vaccinated 
mice. The spleen is the largest secondary lymphoid organ in mammals that 
is easily accessible for lymphocytes found in the blood and consists of areas 
that support the development, maturation, and activation of mature B cells, 
which includes areas (e.g., in the white pulp) where T and B cells interact 
(43, 44). Under a steady-state condition, the spleen has more T and B cells 
than the liver, with the vast majority of the lymphocytes in the mouse spleen
being B cells, and the liver, by default, functions to tolerize immune 
responses through the action of liver-resident cells such as Kupffer cells and 
liver sinusoidal endothelial cells (45). Thus, the higher NS5B-specific 
activation of FTA B220+ cells in the spleen compared to that of the liver in 
the current study is likely due to differences in the cellular composition and 
the microenvironments between the spleen and liver, but this needs to be 
formally evaluated.
Numerous studies have shown that CXCR3 expression is important for 
homing of effector CD4+ and CD8+ T cells to inflammatory sites (46). TRM cells
are known to express higher levels of CXCR3 (12) and CD11a (38) in the liver
compared to TEM and TCM cells, consistent with the observations of the current
study. Fernandez-Ruiz et al. (12) reported that CXCR3 was exclusively 
expressed on CD8+ TRM cells relative to TEM and TCM cell counterparts following
vaccination against P. berghei. However, our findings suggest that NS5B-
specific CD8+ TEM and TCM cells expressed CXCR3, albeit at lower levels 
compared to NS5B-specific CD8+ TRM cells in the liver. The reason for this 
difference is unclear, but it is important to note that Fernandez-Ruiz et al. 
(12) based their analysis on adoptively transferred TCR transgenic PbT-I cells
that were stimulated with vectors encoding or expressing an 8-aa peptide 
(NVY) immunogen. As noted previously, our study was based on the analysis 
of NS5B-specifc polyclonal T cells in wild-type mice following vaccination with
vectors encoding the full-length gt3a NS5B protein, which consists of 
multiple CD4+ and CD8+ T cell epitopes. The results of our study are 
consistent with previous reports which showed that TCM, TEM, and CD11alo and
CD11ahi virus-specific CD8+ T cells express CXCR3 following intranasal Sendai
virus infection (47, 48). HCV-specific TEM and TCM cells isolated from the blood 
and the liver of acutely and chronically infected HCV patients express CXCR3
(49). Furthermore, effector memory CD8+ T cells express CXCR3 following 
intravenous injection of Listeria monocytogenes (50), and lymphocytic 
choriomeningitis virus (LCMV)-specific P14 TCR transgenic CD8+ T cells 
universally expressed CXCR3 48 days postinfection with LCMV Armstrong 
(51).
Several studies have shown that local antigen encounter or deposition 
usually perpetuates the establishment of high numbers of CD8+ TRM cells in 
various anatomical sites, including the liver (12, 52–54). Studies in mice and 
humans suggest that i.v. immunization is the most efficient route to facilitate
local antigen encounter in the liver (13, 37, 55). Intravenous delivery of 
vaccine vectors that can enter hepatocytes and/or the cells surrounding the 
hepatic tissues has been exploited in prime/trap (13) and prime/target (55) 
vaccination approaches to recruit or “pull” systemically primed CD8+ T cells 
into the liver and allow these cells to differentiate into intrahepatic TRM cells. 
Imaging of live mice injected i.d. or i.v. with P. berghei sporozoites suggested
that the sporozoites were reproducibly detected in the liver only after i.v. 
injection, while the parasite load in the liver was 30-fold higher in the i.v.-
injected mice (56). The same study also showed that i.v. compared to i.d. 
injection of irradiated sporozoites elicited a significantly higher proportion of 
CD62L− memory CD8+ T cells and increased protection against live 
sporozoite challenge (56). Intradermal, subcutaneous, and intramuscular 
immunization of humans with radiation-attenuated Plasmodium falciparum 
sporozoites (PfSPZ) also appeared to elicit suboptimal immunity and 
protection against malaria compared to i.v. vaccination (13, 57). Analysis of 
vaccinated nonhuman primates suggests that the increased efficacy of i.v. 
PfSPZ vaccination in humans correlated strongly with the ability of this 
vaccine to elicit long-lived liver-resident CD8+ T cells (13, 57). Furthermore, 
transduced hepatocytes have the capacity to present AAV-encoded antigens 
to CD8+ T cells following i.v. vaccination with AAV (37), and analysis of liver 
biopsy specimens from end-stage hepatitis C patients suggests that HCV 
infection elicits CD11ahi memory CD8+ T cells (15). Collectively these findings
are consistent with our findings, which showed that i.d. vaccination with 
pVAX-NS5B-PRF was less efficient in eliciting intrahepatic T cell immunity and
CD8+ TRM cells compared to i.v. rAAV-NS5B vaccination. Furthermore, antigen
presentation following i.d. DNA immunization occurs in the draining cervical 
lymph nodes (28, 35) and likely does not facilitate local antigen 
encounter/deposition in the liver to establish high numbers of intrahepatic 
CD8+ TRM cells. A caveat with this interpretation is that a recent study that 
analyzed adoptively transferred CD8+ T cells showed that the lodgment of 
CD8+ TRM cells in the liver is both activation and interleukin-15 (IL-15) 
dependent, and inflammatory signals (e.g., type I interferon inducers) can 
enhance the number of intrahepatic CD8+ TRM cells (54). Thus, in addition to 
facilitating local antigen encounter, rAAV-NS5B vaccination could induce 
higher levels of IL-15 and relevant inflammatory signals compared to pVAX-
NS5B-PRF vaccination in order to increase the numbers of intrahepatic CD8+ 
TRM cells.
The prime/trap malaria study (12) is the only study to have evaluated TRM cell
formation following i.v. immunization with AAV (i.e., rAAV-NVY), which was 
performed only 35 days after rAAV-NVY injection. The time point at which we 
evaluated NS5B-specific CD8+ TRM cells was 42 days after the final pVAX-PRF 
(mock) or pVAX-NS5B-PRF vaccination, but it was 56 days after the rAAV-
NS5B vaccination in the rDNA/rAAV/rDNA and mock/rAAV/mock regimens. 
Thus, this is the longest duration following rAAV immunization in which a 
study has evaluated TRM cell formation. The results clearly show that a robust
population of TRM cells can be elicited at least 56 days following i.v. rAAV 
immunization. Furthermore, the numbers of intrahepatic NS5B-specific CD8+ 
T cells that formed 7 and 42 days after the final vaccination in regimens 
involving rAAV-NS5B vaccinations were similar (Fig. 3), with an 
overwhelming majority of the intrahepatic NS5B-specific CD8+ T cells elicited
at day 42 displaying a TRM phenotype in this instance (Fig. 4). This was not 
the case with prime/boost vaccination with pVAX-NS5B-PRF (i.e., in the rDNA/
mock/rDNA regimen), which elicited higher numbers of intrahepatic NS5B-
spcific CD8+ T cells at day 7 compared to day 42 (Fig. 3). Collectively, these 
studies suggest that a stable and durable population of NS5B-specific CD8+ 
TRM cells has formed following rAAV-NS5B vaccination. A caveat is that a 
recent study showed that TRM cells that form in the liver in recipient mice 
adoptively transferred with in vitro-activated OT-I CD8+ T cells or PbT-I cells 
that are later primed with radiation-attenuated sporozoite (RAS) vaccination 
have a half-life of 36 or 28 days, respectively (54). Thus, future studies could 
also determine the half-life of the intrahepatic CD8+ TRM cells that form 
following rAAV vaccination, which will be important for understanding the 
limitations and strengths of using rAAV to elicit a stable population of 
intrahepatic CD8+ TRM cells.
CXCR3 expression is required for T cells to home to inflamed sites and is 
likely to be important for the retention of CD8+ TRM cells in the liver (12), 
although CXCR6 rather than CXCR3 appears to be crucial for the 
establishment of liver-resident CD8+ T cells (58). A recent study also showed 
that there is a threshold level of expression of CD11a necessary to retain 
CD8+ TRM cells in the liver, as heightened expression of CD11a was crucial for
CD8+ TRM cells to remain in the liver (38). We observed that CD11a 
expression was significantly lower on NS5B-specific CD8+ TRM cells in mice 
vaccinated with pVAX-NS5B-PRF (rDNA/mock/rDNA) compared to mice 
vaccinated with rAAV-NS5B, although a similar yet more subtle trend was 
observed relative to CXCR3 expression. This could also explain the inability 
of pVAX-NS5B-PRF vaccination (rDNA/mock/rDNA) to elicit high numbers of 
intrahepatic CD8+ TRM cells or augment the number of these cells in the 
rDNA/rAAV/rDNA regimen compared to rAAV-NS5B vaccination alone (i.e., 
mock/rAAV/mock). Thus, future studies should investigate the factors 
associated with the upregulation of CD11a on intrahepatic CD8+ TRM cells as 
such investigations have the potential to revaluate the manner in which a T-
cell-mediated vaccine is designed against hepatotropic pathogens.
Overall, we evaluated rDNA- and rAAV-based vaccination strategies that can 
be exploited to elicit systemic and intrahepatic HCV-specific T cell immunity, 
which have ramifications for the design of effective vaccines against 
hepatotropic pathogens such as malaria, HBV, and HCV. This study also 
highlights the importance of exploiting hepatotropic vaccine vectors to elicit 
robust and durable intrahepatic cytotoxic CD8+ T cell immunity and TH cell 
responses against HCV in vivo.
MATERIALS AND METHODS
Mice.All studies used 6- to 8-week-old age-matched female BALB/c mice, 
which were purchased from The University of Adelaide Laboratory Animal 
Services and housed in individually HEPA-filtered cages at The Queen 
Elizabeth Hospital, Woodville, Australia. Furthermore, all the animal studies 
were approved and conducted under the guidelines of The University of 
Adelaide and SA Pathology animal ethics committees.
Vaccines and immunizations.We have published several studies (24, 26, 27, 
29) describing how immunogens such as HCV NS proteins were encoded in 
the bicistronic rDNA-PRF vector, which was used to construct pVAX-NS5B-
PRF. The DNA used for vaccinations was isolated from transformed 
Escherichia coli DH5α cells and purified using a Qiagen EndoFree Plasmid 
Giga kit with removal of bacterial endotoxins as per the manufacturer’s 
instructions. For each i.d. vaccination with DNA, mice were anesthetized 
using isoflurane and injected with 50 μg of pVAX-NS5B-PRF or an equimolar 
amount of pVAX-PRF in 40 μl of phosphate-buffered saline (PBS) as we 
described previously (24, 26, 27, 29).
rAAV-NS5B was constructed as we described previously (37). In summary, 
codon-optimized gt3a NS5B and enhanced green fluorescent protein (eGFP) 
were cloned into the multiple-cloning site of pAM2AA (59) under the control 
of a liver-specific enhancer/promoter that is flanked by cis-acting inverted 
terminal repeats. Protease cleavage between NS5B and eGFP was achieved 
by introducing the foot and mouth disease virus 2A (FMDV2A) protease; 
eGFP was included to facilitate analysis of the efficiency of rAAV transduction
of hepatocytes in vivo as we described previously (37). The rAAV-NS5B was 
packaged and pseudoserotyped to capsid 8 following transfection of 
HEK293T cells with pAM2AA encoding NS5B, pXX6 helper plasmid (containing
adenoviral E2a, E4Orf6, and VA RNA genes), and p5E1VD2/8 plasmid 
(containing the Cap gene from AAV-8 and the Rep gene from AAV-2) (60). 
The molar ratio of the plasmids for the transfection was 1:3:1 pAM2AA-NS5B 
to pXX6 to p5E1VD2/8. rAAV-NS5B was harvested and purified using a 
modified polyethylene glycol 8000 (PEG 8000)-NaCl precipitation method as 
described previously (61). The yield of the purified virus was determined 
using the AAVpro titration kit for real-time PCR version 2 (TaKaRa) following 
the protocol for quantitative real-time PCR. For each vaccination with rAAV-
NS5B, 5 × 109 vgc of the virus in 200 μl of PBS was delivered i.v. into the 
lateral tail vein of the mice.
Isolation of cells from the liver and the spleen for analysis.The livers of 
euthanized mice were perfused with 10 to 15 ml of PBS via the portal vein, 
and the perfused livers were meshed through 70-μm-pore cell strainers (BD 
Biosciences). The cells were then resuspended in a 36% isotonic Percoll 
(Sigma-Aldrich) gradient and centrifuged (500 × g at 4°C with no brakes) for 
20 min. The pelleted cells, comprising lymphocytes, were then harvested, 
and red blood cells (RBCs) were lysed before analysis. Isolated spleens were 
meshed through 70-μm-pore cell strainers, and RBC-depleted splenocytes 
were analyzed.
Analysis of KdNS5B451–459 tetramer-positive cells using flow cytometry.A total 
of 1 × 106 to 4 × 106 RBC-depleted splenocytes and lymphocytes derived 
from the liver were seeded in each well of 96-well U-bottom well cell culture 
plates (Sigma-Aldrich) and stained with 40 μl/well of 1:500-diluted fixable 
viability stain 620 (FV620; BD Biosciences) for 15 min at room temperature 
(RT). The cells were then washed twice with PBS and stained with 1:50 
diluted allophycocyanin (APC)-conjugated KdNS5B451–459 tetramer 
(Biomolecular Resource Facility, The John Curtin School of Medical Research, 
Canberra, Australia) in PBS for 45 min at RT in the dark. The cells were then 
washed twice with flow buffer (PBS plus 2% FBS plus 25 mM HEPES plus 5 
mM EDTA) prior to cell surface staining of the samples as described 
previously (62). A cocktail of fluorochrome-conjugated antibodies to mouse 
proteins CD69 (clone H1.2F3; BD Biosciences), CD8 (clone 53-6.7; 
eBioscience), CD62L (clone MEL-14), CXCR3 (clone CXC3-173; BD 
Biosciences), and CD11a (clone M17/4; BD Biosciences) was used for the cell 
surface stain. The fluorochromes conjugated to the antibodies in the cocktail 
include phycoerythrin (PE)-Cy7 (CD69), APC-efluor 780 (CD8), PE (CD62L), 
brilliant violet 421 (CXCR3), and brilliant violet 510 (CD11a). The cells were 
washed twice with 0.5% paraformaldehyde and resuspended in 0.5% 
paraformaldehyde prior to analysis in a Becton, Dickinson FACS Canto II flow 
cytometer. The flow cytometry plots were constructed using the FlowJo 
software (version 8.8.7), and FV620+ (dead) events and doublets were 
excluded prior to analysis of NS5B-specific CD8+ T cells.
FTA analysis.For the FTA in Fig. 1 and 2, naive autologous BALB/c 
splenocytes were serially labeled with the indicated concentrations (Table 1) 
of cell proliferation dye (CPD), cell trace violet (CTV), and carboxyfluorescein 
succinimidyl ester (CFSE) at RT for 5 min as we described previously (29). 
The dye-labeled cells were unpulsed (nil) or pulsed with 10 μg/ml of the 
indicated gt3a NS5B peptide or peptide pool (Table 1) spanning NS5B385–591 
(peptides 61 to 90) for 4 h at 37°C with 5% CO2 as we described previously 
(29). The 90-peptide array spanning the gt3a (K3a/650) NS5B was a gift from
The National Institutes of Health and Biodefence and Emerging Infections 
(BEI) Research Resources, and the sequence for each peptide can be viewed 
using the BEI Research Resources website (www.beiresources.org) under 
catalogue no. NR-4070. A total of 48 × 106 dye-labeled and peptide-pulsed 
target cells (1.5 × 106 per target cell cluster) were resuspended in 200 μl of 
PBS and injected i.v. into the lateral tail vein of mice 13 days after the final 
vaccination with pVAX-NS5B-PRF or placebo as described in the legends to 
Fig. 1 and 2.
For the FTA in Fig. 6 and 7, naive BALB/c splenocytes were serially labeled 
with CPD, CTV, and CFSE as described above and pulsed with the indicated 
concentrations of the peptides or peptide pools of gt3a NS5B as shown in 
Table 2. Subsequently, 20 × 106 dye-labeled and peptide-pulsed target cells 
(1 × 106 per target cell cluster) were resuspended in 200 μl of PBS and 
injected i.v. into the lateral tail vein of mice 42 days after vaccination.
Fifteen hours after the FTA challenge, RBC-depleted cells isolated from the 
livers and spleens of vaccinated mice were stained with PE-Cy7-conjugated 
anti-mouse CD69 (clone H1.2F3; BD Biosciences) and Alexa Fluor 700-
conjugated anti-mouse B220 (RA3-6B2; Invitrogen) for flow cytometric 
analysis as described above. The percentage of specific killing of target cells 
was calculated based on the percentage of FTA cells recovered using the 
formula [(nil target value % – peptide-pulsed target value %)/nil target value 
%] × 100. The plotted values for GMFI of CD69 on B220+ FTA targets were 
calculated using the formula B220+ peptide-pulsed target value (GMFI of 
CD69) − B220+ nil target value (GMFI of CD69).
In vivo depletion of CD4+ T cells and FTA analysis.
Six- to 9-week-old female BALB/c mice were vaccinated with three equimolar
doses (50 μg/dose) of pVAX-PRF (mock) or pVAX-NS5B-PRF at fortnightly 
intervals as described previously (Fig. 1 and 2). Thirteen days after the 3rd 
dose, 7 to 9 mice from the pVAX-NS5B-PRF-vaccinated group were injected 
i.p. with 100 μg/mouse of anti-mouse CD4 depletion antibody (clone GK1.5; 
InVivoMab). Three days after the depletion, FTA cells that were unpulsed or 
pulsed with 10 μg/ml of NS5B225–240, NS5B495–512, P2, or P3 were injected i.v. 
into vaccinated mice 15 h prior to recovery of the injected targets from the 
spleens of mice for the analysis of CD4+ TH cell responses as described in the
legend to Fig. 2.
Epitope prediction and selection.
Fourteen- to 19-aa-long peptide sequences (peptides 61 to 90) from the gt3a
NS5B385–591 region described above were used as input data for epitope 
prediction using IEDB MHC class I epitope prediction algorithm (available at 
www.iedb.org). H2-kd was selected as the parameter for MHC type, and 
epitope prediction length was restricted at 9 amino acids. The “IEDB 
Recommended” approach was the algorithm selected to perform the 
prediction. The result of this prediction was downloaded in .csv format. These
data were then put through an in-house script to match with epitopes that 
have been experimentally validated. The epitope (KdNS5B451–459) that 
matched the experimentally validated epitope found within peptides 69 and 
70 and had high prediction score (where scores closer to 0.0 indicate a 
better predicted epitope) was selected for tetramer synthesis.
Statistical analysis.
Graphs were constructed using the GraphPad Prism 8 software. IBM SPSS 
Statistics software (version 24) was used to perform the normality tests of 
the data distribution and statistical significance of the data, with P values of 
<0.05 considered to be statistically significant. Data were initially analyzed 
using a Shapiro-Wilk test, and normality was assumed for data sets with P 
values of >0.05. A parametric Levene’s test was performed on normally 
distributed data, and homogeneity of variance was assumed for data sets 
with P values of >0.05. To determine the statistical significance for 
comparisons related to normally distributed and homoscedastic data sets, 
one-way analysis of variance (ANOVA) with Tukey’s multiple-comparison test 
was used. For all comparisons related to heteroscedastic data sets, the 
Welch ANOVA with Games-Howell post hoc test was used to determine the 
statistical significance. For nonnormally distributed data sets (P < 0.05 by 
the Shapiro-Wilk test), a nonparametric Levene’s test was performed to 
evaluate the homogeneity of variance of the data. If homogeneity of 
variance was assumed (P > 0.05), a Kruskal-Wallis H test was used to 
determine the statistical significance of the data. All paired comparisons 
between TRM versus TCM cells and TRM versus TEM cells in each vaccination 
group shown in Fig. 4A and Fig. 5B were performed using a paired t test. P 
values for comparisons of the groups shown in Fig. 6 and 7 are given in 
Tables 3 and 4, respectively.
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